Subject: Amendment of parts 2 and 15 of the Commission's Rules to Deregulate the Equipment Authorization Requirements for Digital Devices (ET Docket No. 95–19).

Number of Petitions Filed: 2.

Subject: Amendment of the Commission's Rules to Relocate the Digital Electronic Message Service from the 18 GHz band to the 24 GHz band for Fixed Service (ET Docket No. 97–99).

Number of Petitions Filed: 2.

Subject: Applicant for Authorizations and Licenses of Certain Stations in Various Services (WT Docket No. 97–115).

Number of Petitions Filed: 5.

Federal Communications Commission.

Shirley Suggs,

Chief, Publications Branch.

[FR Doc. 97–25271 Filed 9–23–97; 8:45 am]

BILLING CODE 6712–01–M

FEDERAL RESERVE SYSTEM

Sunshine Act Meeting

AGENCY HOLDING THE MEETING: Board of Governors of the Federal Reserve System.

TIME AND DATE: 12:00 noon, Monday, September 29, 1997.

PLACE: Marriner S. Eccles Federal Reserve Board Building, C Street entrance between 20th and 21st Streets, N.W., Washington, D.C. 20551.

STATUS: Closed.

MATTERS TO BE CONSIDERED:

1. Personnel actions (appointments, promotions, assignments, reassignments, and salary actions) involving individual Federal Reserve System employees.

2. Any items carried forward from a previously announced meeting.

CONTACT PERSON FOR MORE INFORMATION: Mr. Joseph R. Coyne, Assistant to the Board; (202) 452–3204. You may call (202) 452–3207, beginning at approximately 5 p.m. two business days before this meeting, for a recorded announcement of bank and bank holding company applications scheduled for the meeting.

Dated: September 19, 1997.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 97–25407 Filed 9–19–97; 5:06 pm]

BILLING CODE 6210–01–P

FEDERAL TRADE COMMISSION

Sunshine Act Meeting

AGENCY HOLDING THE MEETING: Federal Trade Commission.

TIME AND DATE: 12:00 p.m., Friday, November 7, 1997.

PLACE: Federal Trade Commission Building, Room 532, 6th Street and Pennsylvania Avenue, N.W., Washington, D.C. 20580.

STATUS: Parts of this meeting will be open to the public. The rest of the meeting will be closed to the public.

MATTERS TO BE CONSIDERED: Portions Open to Public: (1) Oral Argument in Brake Guard Products, Inc., Docket 9277

Portions Closed to the Public: (2) Executive Session to follow Oral Argument in Brake Guard Products, Inc., Docket 9277.

CONTACT PERSON FOR MORE INFORMATION: Victoria Streitfeld, Office of Public Affairs: (202) 326–2180. Recorded Message: (202) 326–2711.

Donald S. Clark,

Secretary.

[FR Doc. 97–25521 Filed 9–22–97; 3:40 pm]

BILLING CODE 6750–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary

Agency Information Collection Activities: Submission for OMB Review; Comment Request

The Department of Health and Human Services, Office of the Secretary publishes a list of information collections it has submitted to the Office of Management and Budget (OMB) for clearance in compliance with the Paperwork Reduction Act of 1995 (44 U.S.C. Chapter 35) and 5 CFR 1320.5. The following are those information collections recently submitted to OMB.

1. Study of the Implementation of the Office of Minority Health's Bilingual/Bicultural Service Demonstration Program—NEW—The Office of Minority Health proposes to survey sites participating in its Bilingual/Bicultural demonstration grant program to obtain general information on how the program is being implemented. *Type of Respondents:* demonstration sites; *Number of Respondents:* 47; *Burden Estimate per Response to Verification Survey:* 4 hours; *Total Burden for Verification Survey:* 188 hours; *Burden Estimate per Response to Telephone Interview:* 1 hour; *Total Burden for Telephone Interview:* 47 hours. *Total Study Burden:* 235 hours.

OMB Desk Officer: Allison Eydt.

Copies of the information collection packages listed above can be obtained by calling the OS Reports Clearance Officer on (202) 690–6207. Written comments and recommendations for the proposed information collection should be sent directly to the OMB desk officer designated above at the following address: Human Resources and Housing Branch, Office of Management and Budget, New Executive Office Building, Room 10235, 725 17th Street N.W., Washington, D.C. 20503.

Comments may also be sent to Cynthia Agens Bauer, OS Reports Clearance Officer, Room 503H, Humphrey Building, 200 Independence Avenue S.W., Washington DC, 20201. Written comments should be received within 30 days of this notice.

Dated: September 12, 1997.

Dennis P. Williams,

Deputy Assistant Secretary, Budget.

[FR Doc. 97–25263 Filed 9–23–97; 8:45 am]

BILLING CODE 4150–04–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

Name of Committee: Ophthalmic Devices Panel of the Medical Devices Advisory Committee.

General Function of the Committee: To provide advice and recommendations to the agency on FDA regulatory issues.

Date and Time: The meeting will be held on October 20, 1997, 9 a.m. to 5 p.m., and October 21, 1997, 8:30 a.m. to 5 p.m.

Location: Holiday Inn, Walker and Whetstone Rooms, Two Montgomery Village Ave., Gaithersburg, MD.

Contact Person: Sara M. Thornton, Center for Devices and Radiological Health (HFZ–460), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301–594–2053, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area), code 12396, or from the Internet: http://

www.fda.gov. Please call the Information Line for up-to-date information on this meeting.

Agenda: On October 20, 1997, the committee will discuss issues relating to a premarket approval application for a surface modified intraocular lens (IOL) in addition to a review of an update of the FDA ''grid'' of historical IOL data. A product development protocol (PDP) based on the draft guidance document for monofocal IOL's will be discussed. On October 21, 1997, the committee will discuss proposed extensions to the draft guidance document for refractive surgical lasers, specifically, clinical criteria for the determination of safety and effectiveness for photorefractive keratectomy (PRK) and laser in-situ keratomileusis (LASIK) for myopia, astigmatism, hyperopia, and other refractive indications. A PDP for excimer lasers for PRK will also be discussed. Single copies of the above-mentioned guidance documents are available to the public by contacting the Division of Small Manufacturers Assistance, 1350 Piccard Dr., Rockville, MD 20851, 1–800–638–2041, or from the Internet: http://www.fda.gov/cdrh/draftgui.html.

Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by October 10, 1997. Oral presentations from the public will be scheduled between approximately 8:30 a.m. and 9:30 a.m. on October 20 and 21, 1997. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before October 10, 1997, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: September 16, 1997.

Michael A. Friedman,

Deputy Commissioner for Operations.

[FR Doc. 97–25265 Filed 9-23-97; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

Name of Committee: Dental Plaque Subcommittee Meeting of the Nonprescription Drugs Advisory Committee.

General Function of the Committee: To provide advice and recommendations to the agency on FDA regulatory issues.

Date and Time: The meeting will be held on October 29 and 30, 1997, 8:30 a.m. to 5 p.m.

Location: Holiday Inn, The Ballroom, Two Montgomery Village Ave., Gaithersburg, MD.

Contact Person: Andrea G. Neal, Center for Drug Evaluation and Research (HFD–21), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–443–5455, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area), code 12541. Please call the Information Line for up-to-date information on this meeting.

Agenda: On October 29, 1997, the subcommittee will continue discussion and/or possibly vote on the safety and effectiveness of: C–31G, xylitol, and zinc citrate, as well as the following combination ingredients: (1) Menthol, thymol, eucalyptol, and methyl salicylate; (2) hydrogen peroxide and povidone iodine; and (3) hydrogen peroxide, sodium citrate, zinc chloride, and sodium lauryl sulfate. The subcommittee will also continue discussion of the criteria for over-the-counter (OTC) antiplaque and antigingivitis combination drug products. On October 30, 1997, the subcommittee will discuss the final formulation testing for OTC antiplaque and antigingivitis drug products, and assignments will be made for the review of foreign marketing data supporting OTC antiplaque and antigingivitis ingredients.

Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the subcommittee. Written submissions may be made to the contact person by October 15, 1997. Oral presentations from the public will be scheduled on both days between approximately 9 a.m. and 10 a.m. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before October 15, 1997, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: September 15, 1997.

Michael A. Friedman,

Deputy Commissioner for Operations.

[FR Doc. 97–25266 Filed 9-23-97; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). At least one portion of the meeting will be closed to the public.

Name of Committee: Transmissible Spongiform Encephalopathies Advisory Committee.

General Function of the Committee: To provide advice and recommendations to the agency on FDA regulatory issues.

Date and Time: The meeting will be held on October 6 and 7, 1997, 8:30 a.m. to 5:30 p.m.

Location: Holiday Inn, Versailles Ballrooms I and II, 8120 Wisconsin Ave., Bethesda, MD.

Contact Person: William Freas or Jane S. Brown, Center for Biologics Evaluation and Research (HFM–21), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852, 301–827–0314, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area), code 12388. Please call the Information Line for up-to-date information on this meeting.

Agenda: On October 6, 1997, the committee will discuss FDA regulatory controls to address transmission of Creutzfeldt-Jakob Disease (CJD) by human dura mater products. On October 7, 1997, the committee will discuss appropriate FDA actions concerning CJD-implicated ''secondary'' products (i.e., products in which a CJD-implicated plasma derivative was either added as an excipient or used as a reagent in the manufacturing process).

Procedure: On October 6, 1997, from 8:30 a.m. to 5:30 p.m., and October 7,